 Home > Active Ingredient News > Antitumor Therapy > Hans Biotech initiates Phase 2 clinical trial of CD47/PD-1 bispecific antibody

Hans Biotech initiates Phase 2 clinical trial of CD47/PD-1 bispecific antibody

 Last Update: 2021-06-22
 Source: Internet
 Author: User

Tags

protein interaction

bd biosciences antibodies

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Pharmaceutical Guanlan

Recently, Hansi Biotechnology announced that it has initiated a phase 2 clinical study of the anti-CD47/PD-1 bispecific antibody HX009 injection, and plans to develop the treatment of advanced solid tumors

According to reports, HX009 is a potential "first-in-class" new humanized antibody fusion protein injection, which can simultaneously target PD-1 and CD47

Currently, HX009 is conducting Phase 1 and Phase 2 clinical trials simultaneously in Australia and China

The data shows that as of April 2021, the 7 dose groups in Australia have completed the dose escalation enrollment, and a total of 21 patients have been enrolled in the group.

Note: The original text has been deleted

source:

[1] The Phase II clinical study of the Hansi Bifunctional Antibody HX009 project started.

[2] ASCO: Hans Biosciences announced the latest clinical data of anti-CD47/PD-1 bifunctional antibody HX009 injection at the annual meeting of the American Society of Clinical Oncology in 2021.

▽ attention [drug Mingkang Germany ] micro-channel public number

[Medical attention Mingkang Germany ] ] micro-channel public number

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Hans Biotech initiates Phase 2 clinical trial of CD47/PD-1 bispecific antibody

06-21

Related Products

N-Desmethyl Imatinib 99%

CAS No.: 404844-02-6

Pharma Grade

$1/MT FOB

Topotecan HCl CAS 119413-54-6 for Scientific Research Chemical Reagents Use only topetecan hydrochloride

CAS No.: 119413-54-6

Pharmacy Grade

$4-5/G FOB

Regorafenib 98% white powder 755037-03-7 Regorafenib (BAY 73-4506)

CAS No.: 755037-03-7

Pharmacy Grade

$4-5/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Hans Biotech initiates Phase 2 clinical trial of CD47/PD-1 bispecific antibody

Related Articles

Hans Biotech initiates Phase 2 clinical trial of CD47/PD-1 bispecific antibody